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A B S T R A C T
Background: The Antipsychotic Long-acTing injection in schizOphrenia (ALTO) study was a non-
interventional study across several European countries examining prescription of long-acting injectable
(LAI) antipsychotics to identify sociodemographic and clinical characteristics of patients receiving and
physicians prescribing LAIs. ALTO was also the first large-scale study in Europe to report on the use of
both first- or second-generation antipsychotic (FGA- or SGA-) LAIs.
Methods: Patients with schizophrenia receiving a FGA- or SGA-LAI were enrolled between June 2013 and
July 2014 and categorized as incident or prevalent users. Assessments included measures of disease
severity, functioning, insight, well-being, attitudes towards antipsychotics, and quality of life.
Results: For the 572 patients, disease severity was generally mild-to-moderate and the majority were
unemployed and/or socially withdrawn. 331/572 were prevalent LAI antipsychotic users; of whom 209
were prescribed FGA-LAI. Paliperidone was the most commonly prescribed SGA-LAI (56% of incident
users, 21% of prevalent users). 337/572 (58.9%) were considered at risk of non-adherence. Prevalent LAI
users had a tendency towards better insight levels (PANSS G12 item). Incident FGA-LAI users had more
severe disease, poorer global functioning, lower quality of life, higher rates of non-adherence, and were
more likely to have physician-reported lack of insight.
Conclusions: These results indicate a lower pattern of FGA-LAI usage, reserved by prescribers for
seemingly more difficult-to-treat patients and those least likely to adhere to oral medication.
Crown Copyright © 2018 Published by Elsevier Masson SAS. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
Contents lists available at ScienceDirect
European Psychiatry
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Schizophrenia, typically a chronic mental illness with a high risk
of relapse, impairs cognitive and social functioning and can
negatively impact on health and quality of life [1–3]. Relapse in
people with schizophrenia may lead to hospitalization, reduced
social and work-based functioning, increased stigma and higher risk* Corresponding author.
E-mail address: AGN@lundbeck.com (A.-G. Nylander).
http://dx.doi.org/10.1016/j.eurpsy.2018.04.004
0924-9338/Crown Copyright © 2018 Published by Elsevier Masson SAS. This is an open aof suicide or homicide [4,5]. Antipsychotics are used for relapse
prevention, however non-adherence is a significant barrier [6,7].
Multiple factors can contribute to non-adherence [8] and it is
not only difficult to predict, but also difficult to identify and
measure [9]. Long-acting injectable (LAI) antipsychotics were
developed to improve adherence and reduce the likelihood of
treatment cessation [10–12]. A meta-analysis of 16 naturalistic
mirror-image studies in patients with schizophrenia found LAI
antipsychotics were associated with a significant reduction in
hospitalization, or risk of hospitalization than oral antipsychotics
[13]. Other registry-based naturalistic studies have shown that in
clinical practice, LAIs reduce hospitalizations more effectively thanccess article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ized controlled trials showed no benefit of LAIs over oral
formulations [17]. Differences in methodology between study
types may explain these variable results [17,18]. Despite the
potential for LAIs to impact positively on adherence and clinical
outcomes, prescription rates vary considerably between service
providers [19], and often fall below 20% nationally [7].
Appropriate prescribing of LAI antipsychotics is affected by
several factors including variable pharmacokinetics [20], delayed
resolution of side-effects [7], patient fear of injection, and negative
patient and physician attitudes towards LAIs [7,21]. Consequently,
LAI antipsychotics are often potentially reserved for patients with a
history of relapse and poor compliance to oral medication [7,21–24].
The primary aim of the Antipsychotic Long-acTing injection in
schizOphrenia (ALTO) study was to describe utilization of first-
and second-generation (FGA- and SGA-) LAI antipsychotic treat-
ments, and the sociodemographic and clinical characteristics of
patients with schizophrenia from different countries in Europe, as
well as the characteristics of their prescribing physicians. TheFig. 1. ALTO Study Design. A – The design of the ALTO study. aTime window for the visit a
1.5 months. B – Patient flow-diagram for the ALTO study. FGA: first generation antipsych
were enrolled between 5th July 2013 and 30th June 2014. Enrollment targets were met fo
(95% of the target attained) or for incident FGA-LAI users (20% of the target attained).secondary aim was to identify subgroups of LAI antipsychotic
patients with common attributes to ascertain whether the
sociodemographic and clinical characteristics of patients receiv-
ing FGA- or SGA-LAIs differed.
2. Experimental procedures
2.1. Study design
ALTO was a multi-site, non-interventional study across several
European countries investigating LAI antipsychotics usage in
inpatients and outpatients with schizophrenia, and included the
assessment of patient functioning and insight as recommended by
the US Food and Drug Administration and European Medicines
Agency [25–27].
ALTO study design is shown in Fig. 1A. The baseline population
encompassed 4 LAI user types: FGA- and SGA-LAI incident users and
FGA- and SGA-LAI prevalent users. Incident users were defined as
patients who started LAI treatment at study baseline (14 days) witht 3 months and 6 is  1 month. bTime window for the visits at months 12 and 18 is 
otic, LAI: long-acting injectable, SGA: second generation antipsychotic. All patients
r prevalent FGA-LAI and prevalent SGA-LAI users but not for incident SGA-LAI users
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months; all other patients were considered prevalent users. All
investigators were advised to prescribe in accordance with
recommendations in the local summary of product characteristics
for the chosen drug. Choice of LAI antipsychotic was independent of
the studyprotocoland the decision to includethe patient inthe study.
Local ethics committee approvals were obtained for the study.
2.2. Sample
Sample size estimation was based on 95% confidence interval
(CI) of the Subjective Well-being under Neuroleptic Scale – short
form (SWN-S) total score at study endpoint. Previous reports [28–
34] suggest a change from baseline SWN-S between 4 and 8
points is considered clinically meaningful, with standard devia-
tions (SDs) from 12 to 18 [28–34]. Assuming a SD of 18 in the
SWN-S score, 312 patients provided a 2-sided 95% CI of the score
with a width of 4 points. Considering a global attrition rate of 30%,
450 incident users were targeted for enrollment. It was estimated
that 300 prevalent users should be recruited alongside this, giving
a total planned cohort of 750 patients. Estimated numbers of
patients falling into the FGA- and SGA-LAI categories were
calculated for incident and prevalent users.
Patients were enrolled in Austria, France, Germany, Spain,
Sweden, and the United Kingdom (UK) from hospitals, mental health
centers, private settings, specialized units for LAI antipsychotic
administration, and primary care settings involved in managing
inpatients and/or outpatients treated with LAI antipsychotics.
Recruitment was by naturalistic enrollment of patients who
agreed to participate and met the inclusion criteria. The dates of
first and last patient visits were July 2013 and June 2014,
respectively. Recruitment targets were 250 and 200 for incident
and prevalent users of FGA-LAIs, and 200 and 100 for incident and
prevalent users of SGA-LAIs, respectively. It was intended that each
site should not recruit >10% of the target for France, Germany,
Spain or the UK (>20% for Austria and Sweden).
Inclusion criteria included inpatient/outpatient status, aged
18 years, a diagnosis of schizophrenia (by InternationalTable 1
Study Assessments.
Baseline Only Assessments
Relevance Assessment
Physician Data Physician profile
Physician Attitudes Physician attitude towards long-acting injectables (LAIs)
Patient Data Medical and psychiatric history
Adherence Non-adherence risk
Longitudinal Assessments
Relevance Assessment 
Patient Data Sociodemographics 
Autonomy and caregiver status 
Adverse Events Adverse Drug Reaction assessmenta
Health Economic Relevance Previous and current antipsychotic medication, concomi
Resource use 
Health Status Clinical Global Impression-Severity (CGI-S) 
Functioning Personal and Social Performance (PSP) 
Global Assessment of Functioning (GAF) 
Insight Positive and Negative Syndrome Scale, Item G12 (PANSS
Insight Scale (IS) 
Quality of Life Subjective Well-Being under Neuroleptic Scale, short for
Tolerability and Quality of Life (TooL) 
Patient Attitudes Drug Attitude Inventory – short version (DAI-10) 
Patient-reported outcomes included the IS, SWN-S, TooL and DAI-10. Physician-reporte
a Also assessed at change of treatment.
b Not reported in the baseline report.Classification of Disease-10 criteria), and receipt of FGA- or SGA-
LAI. Exclusion criteria included being pregnant or breastfeeding,
having acute serious or unstable medical conditions (other than
schizophrenia), and having attempted suicide in the past 30 days.
Signed informed consent was required before study enrollment.
2.3. Study assessments
A range of physician and patient assessment tools were utilized
(Table 1).
2.3.1. Physician, patient, and site characteristics
Physician’s site, physician characteristics, and physician-estimat-
ed risk of non-adherence were recorded. At baseline, patient profiles
included sociodemographics (age, gender, education, and profes-
sion), patient autonomy (including living autonomy: with family,
alone, with friend(s) or homeless), and eating autonomy (able to
manage own meal, eats meals regularly with caregiver/family
support, unable to have regular meals). Caregiver status (support of a
nurse/relative/others or absence of caregiver), evidence of social
withdrawal, disease history, relapses within the previous year, co-
morbidities, and treatment-resistant status (previous use of cloza-
pine) were recorded. Patient clinical characteristics included
medical and psychiatric history, autonomy and caregiver status,
previous and current antipsychotic medication, concomitant medi-
cation, and treatment pattern including prior treatment.
2.3.2. Side effects
All adverse drug reactions observed by the investigator or
spontaneously reported by the patient were recorded, and rated
(incident users only) using the Udvalg for Kliniske Undersøgelser
(UKU) side effect rating scale [35].
2.3.3. Patient- and physician-reported clinical assessments
Clinician assessment of severity of the patient’s current mental
illness was rated on the Clinical Global Impression-Severity (CGI-S)
scale [36,37], with remission defined as 2 (‘Normal, not at all ill’ or
‘Borderline ill’). Physician-assessed measurements of patients’ questionnaire
Baseline Time (months) Withdrawal
3 6 12 18
X X X X X X
X X X X X X
Xb X X X X X
tant medication, treatment patterna X X X X X X
X X X X X X
X X X X X X
X X X X X X
X X X X X X
 G12) X X X
X X X
m (SWN-S) X X X X X X
X X X X X
X X X X X X
d outcomes included the CGI-S, PSP, GAF and PANSS G12.
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and Global Assessment of Functioning (GAF) [38]. Item G12 from the
PANSS (Positive and Negative Symptom Scale) was selected for
physicians to rate patients’ lack of insight [39]. The Insight Scale (IS)
was included to complement the PANSS G12 as a more
comprehensive measurement of patient insight and treatment
acceptability [40]. The SWN-S was provided for patients to score
their own well-being on antipsychotic treatment [41]. The
Tolerability and quality of Life (TooL) was used to assess the impact
of side effects on quality of life from the patient perspective [42].
The Drug Attitude Inventory – short version (DAI-10) was used to
assess attitudes towards antipsychotic medication [43].
2.4. Healthcare resource use
Use of resources (hospitalizations, emergency room visits,
psychiatric outpatient consultations, other specialized outpatient
consultations, and skilled nursing facilities), and non-pharmaco-
logic therapies (e.g. institutional support, community treatment,
rehabilitation and psychotherapy) were measured. Direct drug cost
data were not collected.
2.5. Patient subgroups
Four predefined patient subgroups of interest were identified
and analyzed if the subgroup represented 15% of the overall
baseline population:
 Socially withdrawn patients: living alone or homeless, and/or no
caregiver; or unemployed, with marital status defined as single,
divorced/separated or widowed; or who scored “very severe” on
item a (socially useful activities, including work and study) or b
(personal and social relationships) of the PSP.
 Early in disease patients: aged <35 years, or with <5 years since
diagnosis.
 High functioning and young patients: aged 35 years with <10
years since diagnosis, high levels of insight (G12 PANSS scores of
absent-to-mild), GAF scores >61, employed or studying, or living
in an individual residence.
 Low functioning and chronic illness patients: aged 40 years with
15 years since diagnosis, lower levels of insight (PANSS G12
scores of moderate severe to extreme), GAF scores <51,
unemployed or receiving a disability pension, or homeless/
institutionalized.
2.6. Statistical analysis
The baseline analysis population was defined as all patients
who gave informed consent, met the selection criteria, and
completed at least one baseline assessment. Analyses were
performed using SAS1 Version 9.2 and missing items were not
imputed.
Categorical parameters are presented as the number of
responses or percentage of patients in each category. Continuous
parameters are reported as mean  SD. Secondary objectives,
including identification of LAI user subgroups, were addressed by
multiple correspondence analyses on intrinsic and extrinsic
attributes important for LAI treatment choice.
3. Results
3.1. Physician and site characteristics
Overall, 177 physicians participated in the study. The majority
were from the UK (n = 56), Germany (n = 46), Spain (n = 39), orFrance (n = 28), with limited numbers from Austria (n = 5) and
Sweden (n = 3). Physician age was 46.9  10.4 years and 71.2% were
male. Most physicians had 10 years of psychiatrist experience
(77.4%; 18.3  9.9 years). Most (82.1%) of UK-based physicians
worked for the National Health Service (NHS) exclusively and 51.2%
of physicians from other countries worked in an academic setting.
3.2. Patient characteristics
A total of 572/1482 screened patients were enrolled. Targets
were met for prevalent FGA-LAI and SGA-LAI users (209/200 and
122/100, respectively) but not for incident FGA-LAI (51/250; 20% of
target) or SGA-LAI users (190/200; 95% of target) (Fig. 1B).
Patient sociodemographics by country are summarized in
Table 2. Most patients were from Germany, France, or the UK. Mean
patient age was 44.0  13.2 years and 67.3% were male. There were
no significant gender differences between countries. Patients in
Austria were on average younger than in other countries
(29.7  9.5 years). Most patients were single (63.7%) and/or
childless (88.6%), unemployed (81.3%) and/or classified as socially
withdrawn (79.7%). The majority lived in a household (86.4%) and
were considered autonomous with respect to eating or living
conditions (84.8%). The highest proportion of FGA-LAI users was in
the UK (55.2% prevalent and 11.7% incident FGA-LAI users,
respectively) and the highest proportion of SGA-LAI users was
in France (23.3% prevalent and 43.2% incident SGA-LAI users,
respectively, Supplementary Table 1).
Enrolled patients were diagnosed with schizophrenia at a mean
age of 29.7  11.5 years, with mean time since diagnosis of
13.4  11.3 years. Overall, 37.2% were classified as early in disease;
this group had few prevalent FGA-LAI users (Table 3). Incident LAI
users generally had a shorter duration of disease in comparison
with prevalent users and were more likely to have relapsed within
the previous year (Table 3). Almost half of all patients had a history
of substance abuse or dependence (49.5%), and while considerable
proportions suffered from comorbid mood or anxiety disorders
(40.9% and 33.2%, respectively) this was more likely in incident
FGA-LAI users (Table 3).
Overall, 58.9% of patients were considered at risk of non-
adherence (physician-rated), with the highest overall physician-
rated risk observed in incident FGA-LAI users (82.4%). Incident
FGA-LAI users also had the highest rates of documented history of
medication non-adherence (49.0%), inadequate response to
primary antipsychotic treatment (21.6%), prior violent behavior
(25.5%), alcohol abuse (19.6%), and drug abuse (29.4%) (Supple-
mentary Table 2).
3.3. Treatment patterns
At baseline, 56.4% of incident LAI antipsychotic users com-
menced treatment with paliperidone, a SGA-LAI. Paliperidone was
also the most commonly used drug for prevalent LAI users (20.5%),
and was prescribed to around one third of patients overall (n
= 204). For a high proportion of prevalent SGA-LAI users on
risperidone (74.4%), this was the first LAI antipsychotic they had
ever been prescribed, versus a smaller proportion for prevalent
paliperidone users (36.8%). The most common reason given for
FGA-LAI prescription was poor compliance with the previous
antipsychotic. Among LAI antipsychotic users, 39.9% were also
taking 1 oral antipsychotic, with the highest incidence of co-
medication seen in incident FGA-LAI users (58.8%).
In addition to LAI antipsychotics, 30.6%, 8.2%, and 1.0% patients
were receiving 1, 2, or 3 oral antipsychotics, respectively. At least
one other psychotropic medication was taken by 22.0% (anti-
depressants), 22.7% (antiparkinsonians/anticholinergics), 25.9%
(anxiolytics), 9.6% (mood stabilizers/anticonvulsants), and 14.0%
Table 2
Patient Sociodemographics by Country.
Characteristics Austria (n = 7) France (n = 146) Germany (n = 164) Spain (n = 89) Sweden (n = 12) UK (n = 154) Overall (N = 572)
Age, mean, years (SD) 29.7 (9.5) 40.3 (12.3) 46.9 (12.5) 45.4 (11.5) 46.3 (16.9) 44.0 (14.5) 44.0 (13.2)
Male, n (%) 5 (71.4) 106 (72.6) 92 (56.1) 54 (60.7) 10 (83.3) 118 (76.6) 385 (67.3)
BMI, mean (SD)a 27.2 (6.7) 25.8 (4.9) 28.9 (5.5) 28.7 (6.9) 28.2 (6.4) 28.4 (7.1) 27.9 (6.2)
Marital status, n (%)b
Observed 7 (100.0) 146 (100.0) 163 (99.4) 89 (100.0) 11 (91.7) 154 (100.0) 570 (99.7)
Single 6 (85.7) 98 (67.1) 86 (52.8) 62 (69.7) 9 (81.8) 102 (66.2) 363 (63.7)
Divorced/separated 0 (0.0) 22 (15.1) 26 (16.0) 14 (15.7) 0 (0.0) 25 (16.2) 87 (15.3)
Married/living as a couple 1 (14.3) 22 (15.1) 49 (30.1) 10 (11.2) 2 (18.2) 22 (14.3) 106 (18.6)
Widow 0 (0.0) 1 (0.7) 1 (0.6) 3 (3.4) 0 (0.0) 4 (2.6) 9 (1.6)
Unknown 0 (0.0) 3 (2.1) 1 (0.6) 0 (0.0) 0 (0.0) 1 (0.6) 5 (0.9)
Children living in the householdb
Observed 7 (100.0) 146 (100.0) 163 (99.4) 89 (100.0) 11 (91.7) 154 (100.0) 570 (99.7)
Yes, n (%) 0 (0.0) 16 (11.0) 13 (8.0) 10 (11.2) 0 (0.0) 16 (10.4) 55 (9.6)
Mean number (SD)c – 1.9 (1.2) 1.5 (0.7) 1.2 (0.6) – 2.2 (1.9) 1.7 (1.3)
Living area, n (%)d
Institutionalized 0 (0.0) 13 (9.0) 8 (4.9) 5 (5.7) 1 (8.3) 23 (14.9) 50 (8.8)
Household 7 (100.0) 129 (89.0) 142 (87.7) 81 (92.0) 11 (91.7) 121 (78.6) 491 (86.4)
Homeless 0 (0.0) 1 (0.7) 10 (6.2) 2 (2.3) 0 (0.0) 9 (5.8) 22 (3.9)
Unknown 0 (0.0) 2 (1.4) 2 (1.2) 0 (0.0) 0 (0.0) 1 (0.6) 5 (0.9)
Educational status (highest completed level), n (%)e
None 0 (0.0) 0 (0.0) 2 (1.2) 3 (3.4) 0 (0.0) 2 (1.3) 7 (1.3)
Primary to High School 5 (71.4) 91 (64.1) 131 (81.4) 76 (87.4) 3 (30.0) 108 (70.6) 414 (73.9)
Beyond High School 2 (28.6) 37 (26.1) 22 (13.7) 8 (9.2) 7 (70.0) 28 (18.3) 104 (18.6)
Unknown 0 (0.0) 14 (9.9) 6 (3.7) 0 (0.0) 0 (0.0) 15 (9.8) 35 (6.3)
Professional status, n (%)
Employed/student/voluntary 4 (57.1) 30 (20.6) 38 (23.2) 14 (15.7) 3 (25.0) 14 (9.1) 103 (18.0)
Unemployed 3 (42.9) 116 (79.5) 125 (76.2) 74 (83.2) 9 (75.0) 138 (89.6) 465 (81.3)
Unknown 0 (0.0) 0 (0.0) 1 (0.6) 1 (1.1) 0 (0.0) 2 (1.3) 4 (0.7)
Socially withdrawn status, n (%)
Yes 6 (85.7) 118 (80.8) 133 (81.1) 57 (64.0) 11 (91.7) 131 (85.1) 456 (79.7)
BMI: body mass index, SD: standard deviation.
a Overall n = 490; Germany n = 151; UK n = 114; France n = 128; Spain n = 79; Sweden n = 11.
b Overall n = 570; Germany n = 163; Sweden n = 11.
c Of those who have children in the household.
d Overall n = 568; Germany n = 162; France n = 145; Spain n = 88.
e Overall n = 560; Germany n = 161; UK n = 153; France n = 142; Spain n = 87; Sweden n = 10.
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treated with other psychotropic medications were similar between
FGA- and SGA-LAI incident users for anti-depressants, anxiolytics
and mood stabilizers/anticonvulsants. A greater proportion of
incident FGA-LAI users than incident SGA-LAI users were receiving
treatment with antiparkinsonian/anticholinergic medications
(39.2% vs 12.6%, respectively, Supplementary Table 4).
3.4. Side effects
Side effects data were collected for incident users at the time
of change of treatment. Among the non-missing UKU assess-
ments conducted for incident users (n = 216, 89.6%), side effects
were reported in 68.1% of patients (147/216); with slightly more
in FGA-LAI users (n = 34; 66.7%) than in SGA-LAI users (n=113;
59.5%) (Supplementary Table 5). Causality of side effects was
rated as “possible” or “probable” and severity was assessed as
mild-to-severe. The most commonly reported side effects fell
within the Psychic domain and included concentration difficul-
ties (14.1% of completed assessments for incident FGA-LAI users,
14.4% for SGA-LAI users) and lassitude (14.1% for incident FGA-LAI
users, 14.4% for SGA-LAI users). There were fewer reports of
tremor from incident FGA-LAI users than incident SGA-LAI users
(8.8% vs 21.4% of completed assessments; Supplementary
Table 5).
3.5. Patient- and physician-reported clinical assessments
CGI-S score indicated disease severity across patient groups was
mild-to-moderate (60.8% of patients, mean score 3.8). A higherproportion of incident users were in the markedly or severely ill
category (Fig. 2A).
Overall PSP score was 58.1 17.3 (Fig. 2B), indicating marked
difficulties in social functioning for 58.8% of the cohort. In addition,
17.6% of patients had severe difficulties in social functioning and
23.7% mild difficulties. There was a notable difference between
incident and prevalent user PSP scores; incident users generally
scored lower in global functioning (Fig. 2B). Across incident and
prevalent categories, FGA-LAI users scored lower in social and
personal functioning than SGA-LAI users, and incident FGA-LAI
users had the most severe functioning deficits.
Mean GAF score was 57.9  16.6, rating the patients with
moderate symptoms (Fig. 2C). Irrespective of incident/prevalent
category, users of FGA- were more severe compared to SGA-LAI
users, and the incident FGA-LAI users were most severe in global
functioning (Fig. 2C).
Between-group differences in insight, measured by the PANSS
G12, appeared more driven by incident/prevalent status than by
SGA-LAI/FGA-LAI status, and prevalent users tended towards
better levels of insight (Fig. 2D). The proportions of patients for
whom lack of judgment and insight was ‘absent’ or ‘minimal’ (i.e.
no/little perceived problem) were 44.8% and 41.3% for prevalent
FGA- and SGA-LAI users respectively, compared with 34.0% and
24.6% for incident FGA- and SGA-LAI users, respectively. The
proportions of patients for whom lack of judgment and insight was
‘moderate severe’ or ‘severe’ were 17.4% and 11.5% for prevalent
FGA- and SGA-LAI users, compared with 32.0% and 23.5% for
incident FGA- and SGA-LAI users, respectively. Very few patients
(0.5%) were perceived to have ‘extreme’ lack of judgment or
insight. There was no discernible pattern in the patient-scored IS
Table 3
Patient Characteristics and Selected Sociodemographics by LAI Use.
Characteristics, %
(unless otherwise indicated)
Prevalent FGA-LAI
(n = 209)
Prevalent SGA-LAI
(n = 122)
Incident FGA-LAI
(n = 51)
Incident SGA-LAI
(n = 190)
Overall
(N = 572)
p valuea
Age, mean, years 47.9 42.9 38.0 42.0 44.0 <0.0001
Unemployed 88.5 76.2 78.4 77.4 81.3 –
Institutionalized 13.0b 3.3c 3.9d 9.0e 8.8f –
Age at 1st diagnosis, mean, years 30.4g 29.8h 28.2i 29.4j 29.7k 0.6577
Time since diagnosis, mean, years 16.7g 12.5h 9.9i 11.3j 13.4k <0.0001
Early in disease 22.0 42.6 47.1 47.9 37.2 <0.0001
Socially withdrawnl 79.9 84.4 76.5 77.4 79.7 0.4473
Previous relapses in the past year 27.3 31.1 45.1 49.5 37.1 <0.0001
1 previous suicide attempt 29.7 16.4 15.7 17.9 21.7 –
Previous suicide attempts in the past
year
5.7 1.6 7.8 5.8 5.1 0.0965
Mood disorders 38.6m 40.2 54.9 40.0 40.9n –
Depressive comorbidity 55.5 51.6 58.8 50.0 53.1 –
Anxiety disorders 28.5m 32.8 51.0 33.7 33.2n –
Substance abuse/dependence 53.1m 42.6 64.7 45.8 49.5n –
Other psychiatric comorbidities 24.2m 18.0 19.6 18.4 20.5n –
Metabolic disorders 20.7b 18.0 7.8 13.7 16.6o –
Diabetes mellitus 11.1b 5.7 7.8 4.7 7.5o –
Neurologic disorders 18.3b 7.4 9.8 10.5 12.6o –
Mainly previously treated by oralo 0.5 2.5 21.6 31.1 12.9 –
Mainly previously treated by LAIp 92.8 82.0 17.7 12.6 57.2 –
Mainly untreatedq 6.7 15.6 60.8 56.3 29.9 –
Ever treated with clozapine 10.6n 9.8 9.8 6.8 9.1n –
Last used AP was FGA-LAI 19.1 5.7 9.8 13.2 13.5 –
Last used AP was SGA-LAI 6.2 27.0 25.5 12.6 14.5 –
Last used AP was oral 36.4 52.5 66.7 83.7 58.2 –
AP: antipsychotic, FGA-LAI: first generation antipsychotic long-acting injectable, SGA-LAI: second generation antipsychotic long-acting injectable. aIf comparison performed:
for the hypothesis that at least one LAI group differs from another (in the proportion of patients of a specific category, or in the mean value of a given variable [one-way ANOVA
]); bn = 208; cn = 120; dn = 51; en = 189; fn = 568; gn = 172; hn = 112; in = 48; jn = 159; kn = 491; ln = 207; lSocially withdrawn: A patient suffering from social isolation whose
living autonomy is ‘homeless’ or ‘living alone’, and/or caregiver status is ‘absence of caregiver’, or employment status is ‘unemployed’ and marital status is ‘single’, divorced/
separated’ or ‘widow’ and/or items a or b of the PSP scale is ‘very severe’. mn = 570; nn = 571; oPatient treated >50% of the previous year and whose treatment duration with
oral treatment is >50% of the overall treatment duration; pPatient treated >50% of the previous year and whose treatment duration with an LAI is >50% of the overall
treatment duration; qPatient whose treatment duration is 50% of the previous year.
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users (Fig. 2H).
A good level of well-being was suggested across all groups;
mean SWN-S score ranged from 76.8 to 86.3 (Fig. 2E). According to
SWN-S and TooL measures, patients initiating SGA-LAIs had better
quality of life scores than those initiating FGA-LAIs. Incident FGA-
LAI users had the lowest quality of life (Fig. 2E and F).
Patient attitudes towards medication (DAI-10 scores) were
more positive in prevalent than incident users. These results
corresponded to the physician-assessed risk of non-adherence
(highest risk in incident FGA-LAI users [82.4%], followed by
incident SGA-LAI users [58.4%], and prevalent users [FGA-LAI:
56.9%; SGA-LAI: 53.3%], Fig. 2G).
3.6. Healthcare resource use
In the previous year, 36.3% of patients had 1 hospitalization,
mainly due to schizophrenia (93.7%). Incident FGA-LAI users had the
highest rate of hospitalization (52.9%). Overall, 82.2% of patients had
1 psychiatrist visit and 51.6% had 1 GP visit within the past year.
The highest proportion of hospitalized patients at baseline was in the
UK (82/154, 53.6%) while none were hospitalized in Sweden. The
longest stay per patient was in the UK (71.4 days), and shortest in
Spain (33.3 days). The average number of psychiatrist visits was
highest in France (10.8  8.7) and lowest in Sweden (2.3  0.9). In the
previous year, >90% of patients from the UK and Sweden had used
other healthcare professionals or community services, while only
26.2% of patients in Germany utilized these resources.
3.7. Patient subgroups
The proportions of patients in different subgroups varied
between countries (Supplementary Table 3). For most patients inall countries except the UK (48.1%) and Spain (49.4%), the studied
treatment was their first LAI antipsychotic. Spain had the lowest
proportion of socially withdrawn patients (64.0%; versus >80% in
all other countries). The highest proportion of early in disease
patients was observed in Austria (5/7 patients, 71.4%), and the
lowest in Germany (44/164 patients, 26.8%).
When analyzed by LAI antipsychotic user group, incident SGA-
LAI users had the highest proportion of LAI antipsychotic-naïve
patients. The highest proportion of high functioning and young
patients was observed in prevalent SGA-LAI users (16.4%, versus
9.8% overall). The highest proportion of low functioning and
chronic patients was observed among incident FGA-LAI users
(11.8%, versus 7.0% overall).
4. Discussion
European research examining sociodemographic character-
istics, and treatment outcomes of patients receiving FGA- and SGA-
LAIs is limited, with studies confined to 1 country, the effects of
only 1 type of LAI, or 1 patient group [14,44,45]. Considerable
variability also exists in tools used to evaluate functioning, quality
of life, insight and attitudes, and the collection of patient versus
physician data [2].
ALTO was the first large-scale study to report multinational
results on both FGA- and SGA-LAI use in different countries in
Europe. The baseline data indicates a lower pattern of FGA-LAI
usage, with these drugs being reserved for seemingly more
difficult-to-treat patients and those least likely to adhere to oral
therapy. Patients treated with FGA-LAIs tended to have more
severe disease, poorer global functioning, and were more likely to
have moderate-to-severe, or severe lack of insight as reported by
their physician, compared with those treated with SGA-LAIs. This
was most pronounced for incident FGA-LAI users, who were also
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Fig. 2. Physician-Reported and Patient-Reported Assessments. Mean and standard deviation are shown. CGI-S: clinical global impression – severity, DAI: drug attitude
inventory, FGA: first generation antipsychotic, GAF: global assessment of function, LAI: long-acting injectable, PANSS: positive and negative symptom scale, PSP: personal and
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tended towards better levels of insight and this appeared driven
more by incident/prevalent status than by SGA-/FGA-LAI status,
which may be expected as incident users were not treated with
LAIs at the time of enrollment.Sociodemographic and clinical characteristics of the ALTO
baseline population were similar to previously described pop-
ulations of patients with schizophrenia [7,46]. Additionally, the
average severity of disease was comparable to that reported in
other regional studies (Europe, Asia-Pacific, Central America, and
92 P.-M. Llorca et al. / European Psychiatry 52 (2018) 85–94the United States) [10,46–48]. However, the proportion of patients
with a history of substance abuse was higher in our study
population (49.5%) [46]. Average age at first schizophrenic episode
was estimated to be 30 years old – slightly older than in other
published studies (24 and 27 in the Bernado et al [46] and Jaegar
and Rossler [7] studies, respectively). As expected, LAI incident
users tended to have a more recent diagnosis of schizophrenia, and
a history of relapse in the previous year as compared to the
prevalent LAI users [16].
In our study, 22.7% of patients were receiving antiparkinso-
nians/anticholinergics, treatment with which is a commonly used
proxy for extra-pyramidal side effects induced by anti-psychotics
[49]. In our study, fewer incident FGA-LAI users reported
occurrence of tremor than incident SGA-LAI users. This could be
explained by the fact that a greater proportion of incident FGA-LAI
users were being treated with antiparkinsonian/anticholinergic
psychotropic medications than incident SGA-LAI users.
The characteristics of physicians participating in this study
were also similar in patterns of age, mean years of experience and
gender to previous studies [21,50]. This is important as earlier
research has shown that physician characteristics may influence
the selection of a FGA-LAI (associated with greater physician age
and employment in private practice) [51].
Unlike other published studies reporting low or even negative
DAI-10 scores [10,46], the mean DAI-10 score for the overall
ALTO study population represented a moderate subjective
positive attitude to LAI treatment and suggested a lower than
expected rate of non-adherence in our study population.
Although 58.9% of the study population was considered at risk
of non-adherence at baseline, this was only documented for 37%
of patients. Previous reports suggest that rates of non-adherence
to antipsychotics in patients with schizophrenia vary signifi-
cantly (between 30% and 60%) and depend on the definition of
non-adherence [4,52–55]. However, the ALTO study is the first to
involve a multinational sample of prescribers in Europe, which
may make meaningful comparisons difficult. Furthermore, the
relatively low rate of non-adherence observed here may not be
surprising considering LAI antipsychotic treatment is associated
with reduced risk of non-adherence [21], and that our sample of
physicians may be more open to the use of LAI antipsychotics (as
indicated by provider site commitment to patient recruitment).
It may also be that LAIs are considered the preferred, most
convenient option for patients [56,57], and improve the patient-
caregiver relationship.
Differences in hospitalization, length of hospital stay, visits to
psychiatrists, and additional visits to community services are most
likely influenced by country-specific healthcare provisions. Cultural
differences between the different European countries may also
influence communication, symptom manifestation, patient coping
styles, community support systems, and willingness to seek and
maintain treatment [58,59] . There may also be treatment center-
specific differences, including treatment practices and differences in
recommendation lists and local formularies that may impact the
level of LAI antipsychotic prescription. Other factors pertaining to
country-specific culture and sites, as well as physician training,
knowledge and support may also influence prescription patterns of
LAI antipsychotics, as highlighted previously [21].
Among the limitations of this study is the representativeness of
data for Sweden and Austria. There was also a difference in work
settings of the physicians that participated in the ALTO study; most
UK-based physicians worked exclusively within the NHS while
around half of physicians from other countries worked in an
academic setting. Additionally, incident FGA-LAI users were
underrepresented compared to other LAI antipsychotic user
groups – possibly due to a naturalistic change in LAI antipsychotic
prescription patterns in Europe with an evolution of preference forSGA- over FGA-LAIs [60]. The low numbers of patients prescribed
FGA-LAIs may also be attributable to non-participation of forensic
providers in this study. Our prescriber sample may have been more
predisposed to prescription of LAI antipsychotics, which may have
an additional associated bias in favour of SGA-LAI prescribing.
Although the lower numbers in this LAI-user group could trigger
selection bias in the results, the baseline characteristics of these
patients are consistent with previous studies.
Although LAIs were specifically developed to promote treatment
adherence, gaps in knowledge and evidence surrounding their
appropriate usage remains. Improvements in psychopharmacology
and a focus on patient experience could help improve attitudes
towards and appropriate use of LAI antipsychotics [19,61]. Results
from the cross-sectional part of the ALTO study indicate a lower
pattern of FGA-LAI prescription to patients in Europe. Due to a
paucity of data, the reasons for this remain unclear, however it may
be that FGA-LAI may tend to be used in patients with more severe
disease [21,62]. They highlight the necessity for further research to
promote the evidence-based, appropriate use of LAI antipsychotics
for schizophrenia treatment and will be complemented by results
from the longitudinal portion of the ALTO study.
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